University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Michael Geschwind, Ph.D., M.D.

Neurologist

Dr. Michael D. Geschwind is a neurologist at the UCSF Memory and Aging Center who specializes in the assessment and treatment of rapidly progressive dementias, including prion diseases such as Creutzfeldt-Jakob disease (CJD). He helped establish a hospital program for the assessment of rapidly progressive dementias at UCSF Medical Center, the first of its kind in the country. He has also helped establish a clinic for patients with autoimmune encephalopathies. In his research, he studies cognitive dysfunction in movement disorders, such as Huntington's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and other Parkinsonian dementias.

Geschwind earned his medical degree and postdoctoral degree in neuroscience through the Medical Scientist Training Program, sponsored by the National Institutes of Health, at the Albert Einstein College of Medicine in New York. He completed an internship in internal medicine at UCLA Medical Center, a neurology residency at the Johns Hopkins University School of Medicine in Baltimore and a fellowship in behavioral neurology at the UCSF Memory and Aging Center. He is an associate professor of neurology and holds the Michael J. Homer Chair in Neurology in the UCSF School of Medicine.

Clinics

Memory and Aging Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2057
Fax: (415) 476-4800

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Michael Geschwind

Additional Languages

French

Education

Albert Einstein College of Medicine 1996

Residencies

John Hopkins Hospital, Neurology 2000

Fellowships

UCSF Medical Center, Neurobehavior 2002

Selected Research and Publications

  1. Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD. Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy. JAMA Neurol. 2014 May 19.
  2. Uflacker A, Doraiswamy PM, Rechitsky S, See T, Geschwind M, Tur-Kaspa I. Preimplantation Genetic Diagnosis (PGD) for Genetic Prion Disorder Due to F198S Mutation in the PRNP Gene. JAMA Neurol. 2014 Apr 1; 71(4):484-6.
  3. Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, Geschwind MD, Rosen HJ, Boxer AL, Guo W, Pellegrini M, Horvath S, Miller BL, Geschwind DH, Coppola G. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014 Mar; 10(3):e1004211.
  4. Caverzasi E, Henry RG, Vitali P, Lobach IV, Kornak J, Bastianello S, Dearmond SJ, Miller BL, Rosen HJ, Mandelli ML, Geschwind MD. Application of quantitative DTI metrics in sporadic CJD. Neuroimage Clin. 2014; 4:426-35.
  5. Geschwind MD. Doxycycline for Creutzfeldt-Jakob disease: a failure, but a step in the right direction. Lancet Neurol. 2014 Feb; 13(2):130-2.
  6. You SC, Geschwind MD, Sha SJ, Apple A, Satris G, Wood KA, Johnson ET, Gooblar J, Feuerstein JS, Finkbeiner S, Kang GA, Miller BL, Hess CP, Kramer JH, Possin KL. Executive functions in premanifest Huntington's disease. Mov Disord. 2014 Mar; 29 Suppl 3:405-9.
  7. Kim MO, Cali I, Oehler A, Fong JC, Wong K, See T, Katz JS, Gambetti P, Bettcher BM, Dearmond SJ, Geschwind MD. Genetic CJD with a novel E200G mutation in the prion protein gene and comparison with E200K mutation cases. Acta Neuropathol Commun. 2013; 1(1):80.
  8. Takada LT, Geschwind MD. Prion diseases. Semin Neurol. 2013 Sep; 33(4):348-56.
  9. Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony Sh. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis. 2013; 8:177.
  10. Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, Johnson DY, Torres-Chae CC, Finley R, Garcia P, Thai JN, Cheng HQ, Neuhaus JM, Forner SA, Duncan JL, Possin KL, Dearmond SJ, Prusiner SB, Miller BL. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013 Dec 3; 81(23):2015-23.
  11. Lee SE, Tartaglia MC, Yener G, GenÁ S, Seeley WW, Sanchez-Juan P, Moreno F, Mendez MF, Klein E, Rademakers R, Munain AL, Combarros O, Kramer JH, Kenet RO, Boxer AL, Geschwind MD, Gorno-Tempini ML, Karydas AM, Rabinovici GD, Coppola G, Geschwind DH, Miller BL. Neurodegenerative Disease Phenotypes in Carriers of MAPT p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):302-9.
  12. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013 Sep 1; 70(9):1158-66.
  13. Bechtel K, Geschwind MD. Ethics in prion disease. Prog Neurobiol. 2013 Nov; 110:29-44.
  14. Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. 2013; 5:12.
  15. Johnson DY, Dunkelberger DL, Henry M, Haman A, Greicius MD, Wong K, DeArmond SJ, Miller BL, Gorno-Tempini ML, Geschwind MD. Sporadic Jakob-Creutzfeldt disease presenting as primary progressive aphasia. JAMA Neurol. 2013 Feb; 70(2):254-7.
  16. Paterson RW, Torres-Chae CC, Kuo AL, Ando T, Nguyen EA, Wong K, Dearmond SJ, Haman A, Garcia P, Johnson DY, Miller BL, Geschwind MD. Differential diagnosis of jakob-creutzfeldt disease. Arch Neurol. 2012 Dec; 69(12):1578-82.
  17. Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, Geschwind MD, Tartaglia MC, Gao F, Gianni D, Sena-Esteves M, Geschwind DH, Miller BL, Farese RV, Gao FB. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012 Oct 25; 2(4):789-98.
  18. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet. 2012 Aug 1; 21(15):3500-12.
  19. Tartaglia MC, Johnson DY, Thai JN, Cattaruzza T, Wong K, Garcia P, Dearmond SJ, Miller BL, Geschwind MD. Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci. 2012 May; 39(3):304-10.
  20. Kim EJ, Cho SS, Jeong BH, Kim YS, Seo SW, Na DL, Geschwind MD, Jeong Y. Glucose metabolism in sporadic Creutzfeldt-Jakob disease: a statistical parametric mapping analysis of (18) F-FDG PET. Eur J Neurol. 2012 Mar; 19(3):488-93.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.